Citations

Clear

3485 citation(s) found for "Sy, Sarah".

The ABC's of disaster management: Managing apheresis operations during the SARS‐CoV‐2 pandemic
Vossoughi, Sarah , Burgstaler, Edwin A. , Burgstaler, Edwin A , Winters, Jeffrey L. , Schwartz, Joseph E.

Mayo Clinic

Journal of Clinical Apheresis | June 30, 2020 | Volume: 35 | Issue: 4 | Pages: 243-245

10.1002/jca.21803 | PMID 32604469 Get It

Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial
Tamura, Manjula Kurella , Gaussoin, Sarah A. , Chelune, Gordon J. , Gure, Tanya R. , Haley, William E. , Killeen, Anthony A. , Oparil, Suzanne , Rapp, Stephen R. , Supiano, Mark A. , Williamson, Jeff D. , Kurella Tamura, Manjula , Haley, William E , Killeen, Anthony A , Supiano, Mark A , Pajewski, Nicholas M. , Freedman, Barry I. , Rifkin, Dena E. , Weiner, Daniel E.

Mayo Clinic

Journal of the American Society of Nephrology | June 26, 2020 | Volume: 31 | Issue: 9 | Pages: 2122-2132

10.1681/asn.2020010038 | PMID 32591439 Get It

Significance Statement Intensive treatment of hypertension is beneficial for cardiovascular disease and cognitive function, but at the short-term expense of reduced kidney function. In a randomized trial of intensive versus standard systolic BP lowering, the authors found an association between a large decline in eGFR and increased incidence of probable dementia and mild cognitive impairment, but no link between urinary albumin-to-creatinine ratio and occurrence of dementia or mild cognitive impairment. Decline in eGFR occurred more frequently in the intensive treatment group, but did not modify the beneficial effect of intensive treatment on cognitive function. Among hypertensive adults, declining eGFR may be a marker for those at higher risk for dementia or mild cognitive impairment, independent of the intensity of hypertension treatment. Background Intensively treating hypertension may benefit cardiovascular disease and cognitive function, but at the short-term expense of reduced kidney function. Methods We investigated markers of kidney function and the effect of intensive hypertension treatment on incidence of dementia and mild cognitive impairment (MCI) in 9361 participants in the randomized Systolic Blood Pressure Intervention Trial, which compared intensive versus standard systolic BP lowering (targeting <120 mm Hg versus <140 mm Hg, respectively). We categorized participants according to baseline and longitudinal changes in eGFR and urinary albumin-to-creatinine ratio. Primary outcomes were occurrence of adjudicated probable dementia and MCI. Results Among 8563 participants who completed at least one cognitive assessment during follow-up (median 5.1 years), probable dementia occurred in 325 (3.8%) and MCI in 640 (7.6%) participants. In multivariable adjusted analyses, there was no significant association between baseline eGFR <60 ml/min per 1.73 m 2 and risk for dementia or MCI. In time-varying analyses, eGFR decline ≥30% was associated with a higher risk for probable dementia. Incident eGFR <60 ml/min per 1.73 m 2 was associated with a higher risk for MCI and a composite of dementia or MCI. Although these kidney events occurred more frequently in the intensive treatment group, there was no evidence that they modified or attenuated the effect of intensive treatment on dementia and MCI incidence. Baseline and incident urinary ACR ≥30 mg/g were not associated with probable dementia or MCI, nor did the urinary ACR modify the effect of intensive treatment on cognitive outcomes. Conclusions Among hypertensive adults, declining kidney function measured by eGFR is associated with increased risk for probable dementia and MCI, independent of the intensity of hypertension treatment.
Examination of Molecular Effects ofMYLKDeletion in a Patient with Extensive Aortic, Carotid, and Abdominal Dissections That Underlie the Genetic Dysfunction
Macklin, Sarah , Bruno, Katelyn A. , Vadlamudi, Charitha , Helmi, Haytham , Samreen, Ayesha , Hines, Stephanie L., Atwal, Paldeep S. , Caulfield, Thomas R. , Macklin, Sarah K, Mohammad, Ahmed N. , Hines, Stepahnie, Atwal, Paldeep S , Caulfield, Thomas R , Samreen, Ayesha , Bruno, Katelyn A

Mayo Clinic

Case Reports in Medicine | June 22, 2020 | Volume: 2020 | Issue: No issue available | Pages: 1-7

10.1155/2020/5108052 | PMID 32655646 Get It

We describe the phenotype of a patient with extensive aortic, carotid, and abdominal dissections. The proband was found to have a heterozygous deletion of exons 21–34 inMYLK, which is a rare finding, as deletions in this gene have been infrequently reported. We describe this finding following detection in a proband with an extensive history of aortic, carotid, and abdominal dissections. Neoteric molecular modeling techniques to help determine the impact of this deletion on protein function indicated loss of function due to lack of any kinase domain. We also provide the electrostatics calculations from the wild type and mutant variant. Through a combined multiomic approach of clinical, functional, and protein informatics, we arrive at a data fusion for determination of pathogenicity embedded within the genetic code for this particular genetic variant, which, as a platform, continues to broaden its scope across the field of variants of uncertain significance classification.
How I Diagnose Primary Cutaneous Marginal Zone Lymphoma
Gibson, Sarah E. , Swerdlow, Steven H. , Swerdlow, Steven H , Gibson, Sarah E

Mayo Clinic

American Journal of Clinical Pathology | June 22, 2020 | Volume: 154 | Issue: 4 | Pages: 428-449

10.1093/ajcp/aqaa116 | PMID 32808967 Get It

Abstract Objectives Primary cutaneous marginal zone lymphoma (PCMZL) is 1 of the 3 major subtypes of primary cutaneous B-cell lymphoma. The diagnosis of PCMZL may be challenging, as the differential diagnosis includes benign cutaneous lymphoproliferations as well as other primary or secondary cutaneous B-cell or T-cell lymphomas. This review describes our approach to the diagnosis of PCMZL. Methods Two cases are presented that illustrate how we diagnose each of the 2 subtypes of PCMZL. The clinicopathologic features of PCMZL and the ways in which these cases can be distinguished from both benign and other neoplastic entities are emphasized. Results A definitive diagnosis of PCMZL requires the incorporation of histologic and immunophenotypic features, molecular genetic studies in some cases, and just as importantly, clinical findings. Emerging data suggest that the heavy chain class-switched cases may be more like a clonal chronic lymphoproliferative disorder. Conclusions The 2 subtypes of PCMZL create different diagnostic challenges and require the use of a multiparameter approach. Although very indolent, it is important to distinguish PCMZLs from reactive proliferations, because they frequently recur and may require antineoplastic therapies. It is also critical to distinguish PCMZLs from other B- or T-cell lymphomas so that patients are properly evaluated and not overtreated.
Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma
Shah, Kabeer , Neff, Jadee , Erickson, Lori A. , Jackson, Rory A. , Jenkins, Sarah M. , Mansfield, Aaron S. , Moser, Justin C. , Harris, Antoneicka L., Copland, John A. , Halling, Kevin C. , Flotte, Thomas J. , Shah, Kabeer K , Mansfield, Aaron S , Erickson, Lori A

Mayo Clinic

Histopathology | June 21, 2020 | Volume: 77 | Issue: 4 | Pages: 601-610

10.1111/his.14191 | PMID 32564377 Get It

AimsRecently, a novel isoform of anaplastic lymphoma kinase, with alternative transcription initiation (ALKATI), has been described in melanoma and is susceptible to targeted ALK‐inhibitor therapy. Clinical outcomes of patients with ALKATI mutated melanoma as well as correlation with immunohistochemical (IHC) methods have not yet been described.Methods and resultsClinicopathological characteristics were abstracted for 324 patients with metastatic melanoma (MM). IHC, fluorescence in‐situ hybridisation and RNA‐based digital molecular analysis assays were performed on archival tissue from 173 stage III and 192 stage IV tumours. ALKATI was identified in 12.7 and 4.8% stage III and IV tumours, respectively. Discrete presentations of the ALKATI are seen: isolated ALKATI (n = 20) and mixed ALKATI (combined ALKATI and ALKWT; n = 7). Isolated ALKWT expression (n = 4) was seen with no ALK fusions. Stage III patients showed improved survival with ALKATI expression compared to those with ALKWT or no expression [5‐year survival 80, 95% confidence interval (CI) = 57–100% versus 43%, 95% CI = 34–55%, P = 0.013]. Clinicopathological characteristics were not statistically significant. Strong diffuse cytoplasmic staining of ALK IHC (n = 12) has a sensitivity of 52.2%, specificity 100%, PPV of 100% and NPV of 92.5% of detecting isolated ALKATI.ConclusionPresence of ALKATI is a good prognostic indicator in MM. ALK IHC and digital molecular analysis can be incorporated into MM evaluation to identify patients with ALKATI for targeted therapy.
Molecular and Immunohistochemical Analysis of Mucinous Cystic Neoplasm of the Liver
Treeck, Benjamin J. Van , Lotfalla, Mira , Czeczok, Thomas , Mounajjed, Taofic, Moreira, Roger K. , Allende, Daniela , Naini, Bita V. , Westerhoff, Maria , Adsay, Volkan , Kerr, Sarah E. , IIyas, Sumera I, Smoot, Rory L. , Liu, Yuanhang , Davila, Jaime , Graham, Rondell P. , Van Treeck, Benjamin J, Czeczok, Thomas W, I Ilyas, Sumera, Smoot, Rory L , Graham, Rondell P , Davila, Jaime I , Adsay, N Volkan , Reid, Michelle D.

Mayo Clinic

American Journal of Clinical Pathology | June 19, 2020 | Volume: 154 | Issue: 6 | Pages: 837-847

10.1093/ajcp/aqaa115 | PMID 32880620 Get It

Abstract Objectives Mucinous cystic neoplasm of the liver is characterized by neoplastic mucinous and/or biliary epithelium surrounded by ovarian-type stroma. Immunohistochemical studies have shown that the ovarian-type stroma expresses estrogen receptor, suggesting potential hormonal responsiveness. The molecular biology of mucinous cystic neoplasm of the liver remains poorly studied. Methods Transcriptome sequencing and immunohistochemistry were performed on a series of mucinous cystic neoplasms. Results Mucinous cystic neoplasm of the liver exhibited significantly increased RNA expression of ovarian stromal markers WT1, PR, and ER2 and sex cord stromal markers SF-1, inhibin-α, and calretinin compared with nonneoplastic liver. Immunohistochemistry confirmed the RNA-level data. Evidence for sex hormone biosynthesis was identified by significant overexpression of multiple estrogen biosynthetic enzymes. Expression of 17β-hydroxysteroid dehydrogenase 1 was confirmed immunohistochemically. Pathway analysis also identified significant upregulation of the hedgehog and Wnt pathways and significant downregulation of T-helper 1 and T-helper 2 pathways. Conclusions Mucinous cystic neoplasm of the liver recapitulates ovarian stroma at the morphologic, DNA, RNA, and protein levels. These data support the concept that this tumor likely arises from ectopic primitive gonadal tissue and/or stromal cells with capacity to transdifferentiate to ovarian cortical cells.
Increased body mass index does not impact the imaging quality of focused assessment with sonography in trauma
Ifelayo, Oluwatomilona I., Oyemade, Kafayat A. , Tawfic, Sarah, Jeeji, Archana K., Ekstein, Samuel F. , Smoot, William A. , Voelkel, Jacob E., Laughlin, Michael J., Lohse, Christine M. , Kummer, Tobias , Bellamkonda, Venkatesh R. , Ifelayo, Oluwatomilona , Tawfic, Sarah S

Mayo Clinic

Journal of Clinical Ultrasound | June 19, 2020 | Volume: 48 | Issue: 8 | Pages: 452-456

10.1002/jcu.22884 | PMID 32557626 Get It

AbstractBackgroundMany clinicians believe that a patient's body mass index (BMI) affects the likelihood of obtaining high quality ultrasound images.ObjectivesTo assess the hypothesis that increased BMI is associated with worsening focused assessment with sonography in trauma (FAST) image quality.MethodsWe conducted a retrospective single‐center study of FAST examinations performed in a large academic emergency department (ED) with fellowship‐trained emergency ultrasonography faculty performing quality assurance review.ResultsMean (SD) BMI was 28.0 (6.6) among the 302 included studies. The overall quality rating tended to decrease as BMI increased but did not achieve statistical significance in a univariable setting (P = .06) or after adjustment for age and sex (P = .06). Operators perception of image adequacy was largely unaffected by BMI, with the exception of the pericardial view.ConclusionThis study did not identify a statistically significant difference in FAST quality with increased BMI. This result may help assuage clinician concerns about ultrasonography for patients in the ED.
The senescence-associated secretome as an indicator of age and medical risk
Schafer, Marissa , Zhang, Xu , Atkinson, Elizabeth J. , Zhu, Yi , Jachim, Sarah K. , Mazula, Daniel L., Brown, Ashley K. , Berning, Michelle J. , Aversa, Zaira, Kotajarvi, Brian R., Greason, Kevin L. , Suri, Rakesh M. , Cummings, Steven R. , White, Thomas A. , Schafer, Marissa J , Zhang, Xu , Zhu, Yi , Kumar, Amanika , Bruce, Charles J. , Tracy, Russell P. , LeBrasseur, Nathan K.

Mayo Clinic

JCI Insight | June 17, 2020 | Volume: 5 | Issue: 12 | Pages: No page available

10.1172/jci.insight.133668 | PMID 32554926 Get It

Produced by senescent cells, the senescence-associated secretory phenotype (SASP) is a potential driver of age-related dysfunction. We tested whether circulating concentrations of SASP proteins reflect age and medical risk in humans. We first screened senescent endothelial cells, fibroblasts, preadipocytes, epithelial cells, and myoblasts to identify candidates for human profiling. We then tested associations between circulating SASP proteins and clinical data from individuals throughout the life span and older adults undergoing surgery for prevalent but distinct age-related diseases. A community-based sample of people aged 20–90 years (retrospective cross-sectional) was studied to test associations between circulating SASP factors and chronological age. A subset of this cohort aged 60–90 years and separate cohorts of older adults undergoing surgery for severe aortic stenosis (prospective longitudinal) or ovarian cancer (prospective case-control) were studied to assess relationships between circulating concentrations of SASP proteins and biological age (determined by the accumulation of age-related health deficits) and/or postsurgical outcomes. We showed that SASP proteins were positively associated with age, frailty, and adverse postsurgery outcomes. A panel of 7 SASP factors composed of growth differentiation factor 15 (GDF15), TNF receptor superfamily member 6 (FAS), osteopontin (OPN), TNF receptor 1 (TNFR1), ACTIVIN A, chemokine (C-C motif) ligand 3 (CCL3), and IL-15 predicted adverse events markedly better than a single SASP protein or age. Our findings suggest that the circulating SASP may serve as a clinically useful candidate biomarker of age-related health and a powerful tool for interventional human studies.
Conservative Management of Nongangrenous Esophageal and Gastric Pneumatosis
McLaughlin, Sarah A. , Nguyen, Justin H.

Mayo Clinic

The American Surgeon™ | June 17, 2020 | Volume: 73 | Issue: 9 | Pages: 862-864

10.1177/000313480707300906 Get It

Pneumatosis intestinalis, or air within the wall of the gastrointestinal tract, has been documented from the esophagus to the rectum. Its presence can suggest gangrenous changes of the stomach or colon and represents a surgical emergency. However, pneumatosis intestinalis can also occur as a result of a benign, nongangrenous condition. We report the conservative management of a patient with nongangrenous gastric and esophageal pneumatosis.